Sign in
Taking people in GermanyPhase 4

Shingrix vaccine safety in people with psoriasis or psoriatic arthritis

Tests the Shingrix shingles vaccine in adults with psoriasis or psoriatic arthritis.

Key facts

Who runs it
Justus-Liebig-Universitaet Giessen
Where
Bad Bentheim, Bonn, Frankfurt Am Main, Freiburg im Breisgau, Hamburg, Hanover, Marburg, Merzig, Muenster, Munich, Straubing, Wetzlar, and Wuppertal, GermanySee the 16 sites
Registry title
Safety and immunologic response of SHIngrix VAccination in patients suffering from Psoriasis or Psoriatic arthritis
Status
Recruiting
Phase
Phase 4
People taking part
336 people, planned
Started
22 Nov 2023
Expected to end
30 Jun 2029
Type of study
Interventional
Record updated
30 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with psoriasis or psoriatic arthritis whose disease is under control. It studies the safety of the Shingrix shingles vaccine.

Age
18 to 75 years
Sex
All sexes can join.
Disease stage
Psoriasis vulgaris and/or psoriatic arthritis with low disease activity: PASI ≤ 9 for skin disease and DAPSA ≤ 14 for joint disease, depending on the form.
Earlier treatment
No earlier Shingrix (recombinant zoster vaccine). No other shingles or chickenpox vaccine in the last 12 months. No disease flare with treatment escalation in the last 6 months.

Main reasons for not taking part

  • Pregnant or breast feeding
  • History of shingles (herpes zoster) or a chronic infectious disease
  • Cancer not treated with the aim of removing all of the disease, or treated cancer with signs of disease within the last 5 years
  • Allergy to Shingrix or any of its ingredients
  • Another vaccine given too close to the Shingrix dose (30 days for live virus and mRNA vaccines, 8 days for inactivated or subunit vaccines)

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Diagnosis of psoriasis vulgaris and/or psoriatic arthritis
  • Score thresholds depending on disease: a. PASI ≤ 9 and DAPSA ≤ 14 in patients having both psoriasis and psoriasis arthritis b. PASI ≤ 9 in patients presenting with psoriasis vulgaris only c. DAPSA ≤ 14 in patients presenting with psoriasis arthritis without major skin involvement
  • Age ≥ 18 and ≤ 75 years
  • Written informed consent
  • Women of childbearing potential should use at least one of the following contraceptive measures up until 2 months after the second vaccination (week 24 of the study): - progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action - male or female condom with or without spermicide - cap, diaphragm or sponge with spermicide

Who cannot take part

  • Concurrent participation in another interventional AMG trial
  • Prior administration of recombinant zoster vaccine (RZV) at any point in time, or any other herpes zoster or varicella vaccine received less than12 months ago
  • Previous or current history of HZ
  • Live virus and mRNA vaccines cannot be administered within 30 days (before/after) RZV and inactivated/ subunit vaccines within 8 days (before/after) RZV
  • Patients with disease flares within the past 6 months. A disease flare is defined as any therapeutic escalation during the past 6 months prior to screening. This includes new onset of concomitant immunomodulation, change of ongoing immunomodulation, and/or use of glucocorticoids ≥ 10 mg per day prednisolone equivalent
  • History of chronic infectious disease
  • Past or current history of cancer not curatively treated. Curatively treated malignancies must be without evidence of disease for a minimumof 5 years upon enrollment
  • Patients with any other significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere withcompletion of the study
  • Hypersensitivity to the active substance or to any of the other substance of Shingrix
  • Subject pregnant or breast feeding

Where in Germany

  • Thermalsole und Schwefelbad Bentheim GmbHBad Bentheim, GermanyTaking people
  • Universitaetsklinikum Bonn AöRBonn, GermanyTaking people
  • Goethe University FrankfurtFrankfurt Am Main, GermanyTaking people
  • Infektio Research GmbH & Co. KGFrankfurt Am Main, GermanyTaking people
  • Medical Center- University of FreiburgFreiburg im Breisgau, GermanyTaking people
  • ICH Study Center Gmbh & Co. KGHamburg, GermanyTaking people
  • University Medical Center Hamburg-EppendorfHamburg, GermanyTaking people
  • Rheumatologische Praxis Hannover GbRHanover, GermanyTaking people
  • Philipps-Universitaet MarburgMarburg, GermanyTaking people
  • Hms GmbHMerzig, GermanyTaking people
  • Universitaet MuensterMuenster, GermanyTaking people
  • Universitaetsklinikum Muenster AöRMuenster, GermanyTaking people
  • Klinikum der Universitaet Muenchen AöRMunich, GermanyTaking people
  • Barmherzige Brueder gemeinnuetzige Traeger GmbHStraubing, GermanyTaking people
  • Studienteam Lahn-Dill-Siegerland GbRWetzlar, GermanyTaking people
  • Klinikverbund St. Antonius und St. Josef GmbHWuppertal, GermanyTaking people

About the trial

What the trial wants to find out

To investigate the safety of the vaccine in terms of underlying disease activity in patients with psoriasis or psoriatic arthritis.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Safety and immunogenicity of Shingrix vaccination in patients suffering from Psoriasis or Psoriatic arthritis
Plain-language title
Shingrix vaccine safety in people with psoriasis or psoriatic arthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
30 April 2026